Efficacy and safety of prostaglandin analogues in patients with predominantly primary open-angle glaucoma or ocular hypertension: A meta-analysis

Clinical Ophthalmology

Volumn 3, Issue 1, 2009, Pages 447-456

  Eyawo, Oghenowede ^a   Nachega, Jean ^b,c   Lefebvre, Pierre ^d   Meyer, David ^e   Rachlis, Beth ^f   Lee, Chia Wen ^g   Kelly, Steven ^g   Mills, Edward ^h  

^a SIMON FRASER UNIVERSITY   (Canada)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d MOORFIELDS EYE HOSPITAL   (United Kingdom)

^e STELLENBOSCH UNIVERSITY   (South Africa)

^f UNIVERSITY OF TORONTO   (Canada)

^g PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^h MCMASTER UNIVERSITY   (Canada)

Author keywords

Bimatoprost; Latanoprost; Ocular hypertension; Primary open angle glaucoma; Prostaglandin analogues; Travoprost

Indexed keywords

BIMATOPROST; LATANOPROST; TRAVOPROST;

ARTICLE; CLINICAL TRIAL; CONJUNCTIVAL HYPEREMIA; DRUG EFFICACY; DRUG SAFETY; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; META ANALYSIS; OPEN ANGLE GLAUCOMA; OUTCOME ASSESSMENT; SYSTEMATIC REVIEW;

EID: 70849124764     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Coleman AL. Glaucoma. Lancet. 1999;354:1803-1810.
2. Maier PC, Funk J, Schwarzer G, Antes G, Falck-Ytter YT. Treatment of ocular hypertension and open angle glaucoma: meta-analysis of randomised controlled trials. BMJ. 2005;331:134.
3. Weigert G, Findl O, Luksch A, et al. Effects of moderate changes in intraocular pressure on ocular hemodynamics in patients with primary open-angle glaucoma and healthy controls. Ophthalmology. 2005;112:1337-1342.
4. Gordon MO, Beiser JA, Brandt JD, et al. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:714-720; discussion 829-730.
5. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701-713; discussion 829-730.
6. Vass C, Hirn C, Sycha T, Findl O, Bauer P, Schmetterer L. Medical interventions for primary open angle glaucoma and ocular hypertension. Cochrane Database Syst Rev. 2007:CD003167.
7. Hodge WG, Lachaine J, Steffensen I, et al. The efficacy and harm of prostaglandin analogues for IOP reduction in glaucoma patients compared to dorzolamide and brimonidine: a systematic review. Br J Ophthalmol. 2008;92:7-12.
8. van der Valk R, Webers CA, Schouten JS, Zeegers MP, Hendrikse F, Prins MH: Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. Ophthalmology. 2005;112:1177-1185.
9. van der Valk R, Schouten JS, Webers CA, et al. The impact of a nation-wide introduction of new drugs and a treatment protocol for glaucoma on the number of glaucoma surgeries. J Glaucoma. 2005;14:239-242.
10. Burr J, Azuara-Blanco A, Avenell A. Medical versus surgical interventions for open angle glaucoma. Cochrane Database Syst Rev. 2005: CD004399.
11. Li N, Chen XM, Zhou Y, Wei ML, Yao X. Travoprost compared with other prostaglandin analogues or timolol in patients with open-angle glaucoma or ocular hypertension: meta-analysis of randomized controlled trials. Clin Experiment Ophthalmol. 2006;34:755-764.
12. Denis P, Lafuma A, Khoshnood B, Mimaud V, Berdeaux G. A meta-analysis of topical prostaglandin analogues intra-ocular pressure lowering in glaucoma therapy. Curr Med Res Opin. 2007;23:601-608.
13. Fung AT, Reid SE, Jones MP, Healey PR, McCluskey PJ, Craig JC. Meta-analysis of randomised controlled trials comparing latanoprost with brimonidine in the treatment of open-angle glaucoma, ocular hypertension or normal-tension glaucoma. Br J Ophthalmol. 2007;91:62-68.
14. Cheng JW, Wei RL. Meta-analysis of 13 randomized controlled trials comparing bimatoprost with latanoprost in patients with elevated intraocular pressure. Clin Ther. 2008;30:622-632.
15. American Academy of Ophthalmology Preferred Practice Pattern: Primary open-angle glaucoma (2005) - http://one.aao.org/CE/PracticeGuidelines/PPP.aspx? sid=ca9ec1b5-2567-4e85-96f6-b6540e5ac5a1. Accessed July 6, 2009.
16. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA. 1995;273:408-412.
17. Devereaux PJ, Manns BJ, Ghali WA, et al. Physician interpretations and textbook definitions of blinding terminology in randomized controlled trials. JAMA. 2001;285:2000-2003.
18. McAlister FA, Laupacis A, Wells GA, Sackett DL. Users' Guides to the Medical Literature: XIX. Applying clinical trial results B. Guidelines for determining whether a drug is exerting (more than) a class effect. JAMA. 1999;282:1371-1377.
19. Le Henanff A, Giraudeau B, Baron G, Ravaud P. Quality of reporting of noninferiority and equivalence randomized trials. JAMA. 2006;295:1147-1151.
20. Piaggio G, Elbourne DR, Altman DG, Pocock SJ, Evans SJ. Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. JAMA. 2006;295:1152-1160.
21. Meade MO, Guyatt GH, Cook RJ, et al. Agreement between alternative classifications of acute respiratory distress syndrome. Am J Respir Crit Care Med. 2001;163:490-493.
22. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-188.
23. Sheehe PR. Combination of log relative risk in retrospective studies of disease. Am J Public Health Nations Health. 1966;56:1745-1750.
24. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539-1558.
25. Whitcup SM, Cantor LB, VanDenburgh AM, Chen K. A randomised, double masked, multicentre clinical trial comparing bimatoprost and timolol for the treatment of glaucoma and ocular hypertension. Br J Ophthalmol. 2003;87:57-62.
26. Cantor LB, Hoop J, Morgan L, Wudunn D, Catoira Y. Intraocular pressure-lowering efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension. Br J Ophthalmol. 2006;90:1370-1373.
27. Cantor LB, WuDunn D, Cortes A, Hoop J, Knotts S. Ocular hypotensive efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension. Surv Ophthalmol. 2004;49 Suppl 1: S12-S18.
28. Koz OG, Ozsoy A, Yarangumeli A, Kose SK, Kural G. Comparison of the effects of travoprost, latanoprost and bimatoprost on ocular circulation: a 6-month clinical trial. Acta Ophthalmol Scand. 2007;85:838-843.
29. Hepsen IF, Ozkaya E. 24-h IOP control with latanoprost, travoprost, and bimatoprost in subjects with exfoliation syndrome and ocular hypertension. Eye. 2007;21:453-458.
30. Cellini M, Caramazza R, Bonsanto D, Bernabini B, Campos EC. Prostaglandin analogs and blood-aqueous barrier integrity: a flare cell meter study. Ophthalmologica. 2004;218:312-317.
31. Parrish RK, Palmberg P, Sheu WP. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol. 2003;135:688-703.
32. Arcieri ES, Santana A, Rocha FN, Guapo GL, Costa VP. Blood-aqueous barrier changes after the use of prostaglandin analogues in patients with pseudophakia and aphakia: a 6-month randomized trial. Arch Ophthalmol. 2005;123:186-192.
33. Topouzis F, Melamed S, Danesh-Meyer H, et al. A 1-year study to compare the efficacy and safety of once-daily travoprost 0.004%/timolol 0.5% to once-daily latanoprost 0.005%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension. Eur J Ophthalmol. 2007;17:183-190.
34. Cardascia N, Vetrugno M, Trabucco T, Cantatore F, Sborgia C. Effects of travoprost eye drops on intraocular pressure and pulsatile ocular blood flow: a 180-day, randomized, double-masked comparison with latanoprost eye drops in patients with open-angle glaucoma. Current Therapeutic Research. 2003;64:389-400.
35. Parmaksiz S, Yuksel N, Karabas VL, Ozkan B, Demirci G, Caglar Y. A comparison of travoprost, latanoprost, and the fixed combination of dorzolamide and timolol in patients with pseudoexfoliation glaucoma. Eur J Ophthalmol. 2006;16:73-80.
36. Netland PA, Landry T, Sullivan EK, et al. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2001;132:472-484.
37. Noecker RJ, Earl ML, Mundorf TK, Silverstein SM, Phillips MP. Comparing bimatoprost and travoprost in black Americans. Curr Med Res Opin. 2006;22:2175-2180.
38. Noecker RJ, Earl ML, Mundorf T, Peace J, Williams RD. Bimatoprost 0.03% versus travoprost 0.004% in black Americans with glaucoma or ocular hypertension. Adv Ther. 2003;20:121-128.
39. Dirks MS, Noecker RJ, Earl M, Roh S, Silverstein SM, Williams RD. A 3-month clinical trial comparing the IOP-lowering efficacy of bimatoprost and latanoprost in patients with normal-tension glaucoma. Adv Ther. 2006;23:385-394.
40. Gandolfi S, Simmons ST, Sturm R, Chen K, VanDenburgh AM. Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension. Adv Ther. 2001;18:110-121.
41. Noecker RS, Dirks MS, Choplin NT, Bernstein P, Batoosingh AL, Whitcup SM. A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol. 2003;135:55-63.
42. Mundorf T, Noecker RJ, Earl M: A multicenter, investigator-masked, randomized comparison of the IOP-lowering efficacy of bimatoprost 0.03% versus travoprost 0.004% in African Americans with glaucoma or ocular hypertension. Invest Ophthalmol Vis Sci. 2004;45:E-Abstract 4502.
43. Eyawo O, Lee CW, Rachlis B, Mills EJ. Reporting of noninferiority and equivalence randomized trials for major prostaglandins: A systematic survey of the ophthalmology literature. Trials. 2008;9:69.
44. Sowka JW, Gurwood AS, Kabat AG: Handbook of Ocular Disease Management: Review of Optometry. 2002. http://www.revoptom.com/HANDBOOK/hbhome.htm. Accessed July 17, 2009.
45. Owen CG, Carey IM, de Wilde S, Whincup PH, Wormald R, Cook DG. Persistency with medical treatment for glaucoma and ocular hypertension in the United Kingdom: 1994-2005. Eye. 2008. [Epub ahead of print].
46. Feldman RM. Conjunctival hyperemia and the use of topical prostaglandins in glaucoma and ocular hypertension. J Ocul Pharmacol Ther. 2003;19:23-35.
47. Friedman DS, Hahn SR, Gelb L, et al. Doctor-patient communication, health-related beliefs, and adherence in glaucoma results from the Glaucoma Adherence and Persistency Study. Ophthalmology. 2008;115:1320-1327.
48. Hollo G: The side effects of the prostaglandin analogues. Expert Opin Drug Saf. 2007;6:45-52.
49. Baudouin C, Garcher C, Haouat N, Bron A, Gastaud P. Expression of inflammatory membrane markers by conjunctival cells in chronically treated patients with glaucoma. Ophthalmology. 1994;101:454-460.